TNF-blocking agents and tuberculosis: New drugs illuminate an old topic

Rheumatology

Volumn 44, Issue 6, 2005, Pages 714-720

  Keane, J ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

TNF; Tuberculosis

Indexed keywords

ADALIMUMAB; BCG VACCINE; CYTOKINE; ETANERCEPT; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; METHOTREXATE; MONOCLONAL ANTIBODY; NEW DRUG; PENTOXIFYLLINE; PLACEBO; PYRAZINAMIDE; RIFAMPICIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR ANTIBODY; ANTIRHEUMATIC AGENT; IMMUNOGLOBULIN G; TNFR FC FUSION PROTEIN; TNFR-FC FUSION PROTEIN; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ANAMNESIS; CHRONIC INFLAMMATION; CLINICAL TRIAL; CROHN DISEASE; DIAGNOSTIC ACCURACY; DOSE RESPONSE; DRUG HALF LIFE; DRUG MECHANISM; DRUG POTENTIATION; DRUG SAFETY; GRANULOMA; HUMAN; IMMUNE RESPONSE; IMMUNOMODULATION; LATENT TUBERCULOSIS INFECTION; LIVER TOXICITY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRESCRIPTION; PRIORITY JOURNAL; REINFECTION; REVIEW; RHEUMATOID ARTHRITIS; SCREENING; THORAX RADIOGRAPHY; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; DISEASE PREDISPOSITION; DRUG ANTAGONISM; DRUG EFFECT; IMMUNITY; IMMUNOLOGY; SKIN TEST;

ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; DISEASE SUSCEPTIBILITY; DRUG SYNERGISM; HUMANS; IMMUNITY; IMMUNOGLOBULIN G; RECEPTORS, TUMOR NECROSIS FACTOR; SKIN TESTS; TUBERCULOSIS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 24944529247     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/keh567     Document Type: Review

References (58)

1. Warris A, Bjorneklett A, Gaustad P. Invasive pulmonary aspergillosis associated with infliximab therapy. N Engl J Med 2001;344:1099-100.
2. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261-5.
3. Slifman NR, Gershon SK, Lee JH, Edwards ET, Braun MM. Listeria monocytogenes infection as a complication of treatment with tumor necrosis factor alpha-neutralizing agents. Arthritis Rheum 2003;48:319-24.
4. Netea MG, Radstake T, Joosten LA, van der Meer JW, Barrera P, Kullberg BJ. Salmonella septicemia in rheumatoid arthritis patients receiving anti-tumor necrosis factor therapy: Association with decreased interferon-gamma production and Toll-like receptor 4 expression. Arthritis Rheum 2003;48:1853-7.
5. Keane J, Gershon S, Wise RP et al. Tuberculosis associated with infliximab, a tumor necrosis factor α-neutralizing agent. N Engl J Med 2001;345:1098-104.
6. Tufariello JM, Chan J, Flynn JL. Latent tuberculosis: Mechanisms of host and bacillus that contribute to persistent infection. Lancet Infect Dis 2003;3:578-90.
7. Israel H, Hetherington H, Ord J. A study of tuberculosis among students of nursing. JAMA 1941;117:461-73.
8. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 2000;161:S221-47.
9. Horsburgh CR Jr. Priorities for the treatment of latent tuberculosis infection in the United States. N Engl J Med 2004;350:2060-7.
10. Ormerod LP. Tuberculosis and anti-TNF-α treatment. Thorax 2004; 59:921.
11. Salmon D. Recommendations about the prevention and management of tuberculosis in patients taking infliximab. Joint Bone Spine 2002;69:170-2.
12. Tuberculosis associated with blocking agents against tumor necrosis factor-alpha - California, 2002-2003. MMWR Morb Mortal Wkly Rep 2004;53:683-6.
13. Ledinghan J, Deighton C. Update on the British Society for Rheumatology guidelines for prescribing TNFα blockers in adults with rheumatoid arthritis (update of previous guidelines of April 2001). Rheumatology 2005;44:157-63.
14. Scallon B, Cai A, Solowski N et al. Binding and functional comparisons of two types of tumor necrosis factor antagonists. J Pharmacol Exp Ther 2002;301:418-26.
15. Keane J, Gershon S, Braun M. Tuberculosis and treatment with infliximab. N Engl J Med 2002;346:623-6.
16. Wallis RS, Broder M, Wong J, Beenhouwer D. Granulomatous infections due to tumor necrosis factor blockade: Correction. Clin Infect Dis 2004;39:1254-5.
17. Centocor I. Remicade (infliximab). Product label 2004.
18. Rieder HL, Snider DE Jr, Cauthen GM. Extrapulmonary tuberculosis in the United States. Am Rev Respir Dis 1990;141:347-51.
19. Wolfe F, Michaud K, Anderson J, Urbansky K. Tuberculosis infection in patients with rheumatoid arthritis and the effect of infliximab therapy. Arthritis Rheum 2004;50:372-9.
20. Nakelchik M, Mangino JE. Reactivation of histoplasmosis after treatment with infliximab. Am J Med 2002;112:78.
21. Ellerin T, Rubin RH, Weinblatt ME. Infections and anti-tumor necrosis factor alpha therapy. Arthritis Rheum 2003;48:3013-22.
22. Fischkoff S. Preliminary analysis of phase i and ii safety data from the adalimumab (D2E7) clinical trials program. Proceedings of Advances in Targeted Therapies Meeting, Bahamas, April 27-May 1, 2001.
23. Perez J, Kupper H, Radin A, Spencer-Green G. Impact of screening for latent TB prior to initiating anti-TNF therapy. San Antonio (TX)(Abstract): American College of Rheumatology, 2005.
24. Mohan AK, Cote TR, Block JA, Manadan AM, Siegel JN, Braun MM. Tuberculosis following the use of etanercept, a tumor necrosis factor inhibitor. Clin Infect Dis 2004;39:295-9.
25. Gomez-Reino JJ, Carmona L, Valverde VR, Mola EM, Montero MD. Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: A multicenter active-surveillance report. Arthritis Rheum 2001;48:2122-7.
26. Roach DR, Bean AGD, Demangel C, France MP, Briscoe H, Britton WJ. TNF regulates chemokine induction essential for cell recruitment, granuloma formation, and clearance of mycobacterial infection. J Immunol 2002;168:4620-7.
27. Lopez Ramirez G, Rom W et al. Mycobacterium tuberculosis alters expression of adhesion molecules on monocytic cells. Infect Immun 1994;62:2515-20.
28. Keane J, Shurtleff B, Kornfeld H. TNF-dependent BALB/c murine macrophage apoptosis following Mycobacterium tuberculosis infection inhibits bacillary growth in an IFN-gamma independent manner. Tuberculosis (Edinb) 2002;82:55.
29. Zganiacz A, Santosuosso M, Wang J et al. TNF-α is a critical negative regulator of type 1 immune activation during intracellular bacterial infection. J Clin Invest 2004;113:401-13.
30. Flynn JL, Goldstein MM, Chan J et al. Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. Immunity 1995;2:561-72.
31. Bean AG, Roach DR, Briscoe H et al. Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. J Immunol 1999;162:3504-11.
32. Mohan VP, Scanga CA, Yu K et al. Effects of tumor necrosis factor alpha on host immune response in chronic persistent tuberculosis: Possible role for limiting pathology. Infect Immun 2001;69:1847-55.
33. Algood HM, Lin PL, Yankura D, Jones A, Chan J, Flynn JL. TNF influences chemokine expression of macrophages in vitro and that of CD11b+ cells in vivo during Mycobacterium tuberculosis infection. J Immunol 2004;172:6846-57.
34. Turner J, Frank AA, Brooks JV, Marietta PM, Orme IM. Pentoxifylline treatment of mice with chronic pulmonary tuberculosis accelerates the development of destructive pathology. Immunology 2001;102:248-53.
35. Olleros ML, Guler R, Corazza N et al. Transmembrane TNF induces an efficient cell-mediated immunity and resistance to Mycobacterium bovis Bacillus Calmette-Guerin infection in the absence of secreted TNF and lymphotoxin-α. J Immunol 2002; 168:3394-3401.
36. Lugering A, Schmidt M, Lugering N, Panels HG, Domschke W, Kucharzik T. Infliximab induces apoptosis in monocytes from patients with chronic active Crohn's disease by using a caspase-dependent pathway. Gastroenterology 2001;121:1145-57.
37. Van den Brande JM, Braat H, van den Brink GR et al. Infliximab but not etanercept induces apoptosis in lamina propria T-lymphocytes from patients with Crohn's disease. Gastroenterology 2003;124:1774-85.
38. Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J. Down-regulation of the nonspecific and antigen-specific T cell cytokine response in ankylosing spondylitis during treatment with infliximab. Arthritis Rheum 2003;48:780-90.
39. Popa C, Netea M, Barrerra P, Kulberg B, Van der Meer J. Cytokine production of stimulated whole blood cultures in rheumatoid arthritis patients receiving anti-TNF agents. Eur Cytokine Netw 2003;14:61.
40. Wood KL, Hage CA, Knox KS et al. Histoplasmosis after treatment with anti-tumor necrosis factor-α therapy. Am J Respir Crit Care Med 2003;167:1279-82.
41. Bergstrom L, Yocum DE, Ampel NM et al. Increased risk of coccidioidomycosis in patients treated with tumor necrosis factor alpha antagonists. Arthritis Rheum 2004;50:1959-66.
42. Obrador A, Lopez San Roman A, Munoz P, Fortun J, Gassull MA. [Consensus guideline on tuberculosis and treatment of inflammatory bowel disease with infliximab. Spanish Working Group on Crohn Disease and Ulcerative Colitis]. Gastroenterol Hepatol 2003; 26:29-33.
43. Long R, Gardam M. Tumour necrosis factor-alpha inhibitors and the reactivation of latent tuberculosis infection. CMAJ 2003;168:1153-6.
44. Gardam MA, Keystone EC, Menzies R et al. Anti-tumour necrosis factor agents and tuberculosis risk: Mechanisms of action and clinical management. Lancet Infect Dis 2003;3:148-55.
45. Taylor JC, Orkin R, Lanham J. Tuberculosis following therapy with infliximab may be refractory to antibiotic therapy. Rheumatology 2003;42:901-2.
46. Jasmer RM, Nahid P, Hopewell PC. Treatment of latent tuberculosis infection. N Engl J Med 2003;348:1292-3.
47. Hamilton CD. Tuberculosis in the cytokine era: What rheumatologists need to know. Arthritis Rheum 2003;48:2085-91.
48. Mazurek GH, LoBue PA, Daley CL et al. Comparison of a whole-blood interferon gamma assay with tuberculin skin testing for detecting latent Mycobacterium tuberculosis infection. JAMA 2001;286:1740-7.
49. Ewer K, Deeks J, Alvarez L et al. Comparison of T-cell-based assay with tuberculin skin test for diagnosis of Mycobacterium tuberculosis infection in a school tuberculosis outbreak. Lancet 2003; 361:1168-73.
50. Orenstein R, Kolls JK, Zhang Z, Mannon PJ, Fuss IJ, Strober W. Anti-interleukin-12 antibody for active Crohn's disease. N Engl J Med 2005;52:627-8.
51. Parra Ruiz J, Ortego Centeno N, Raya Alvarez E. Development of tuberculosis in a patient treated with infliximab who had received prophylactic therapy with isoniazid. J Rheumatol 2003;30:1657-8.
52. Kim HA, Yoo CD, Baek HJ et al. Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population. Clin Exp Rheumatol 1998;16:9-13.
53. van Rie A, Warren R, Richardson M et al. Exogenous reinfection as a cause of recurrent tuberculosis after curative treatment. N Engl J Med 1999;341:1174-9.
54. Priest DH, Vossel LF Jr, Sherfy EA, Hoy DP, Haley CA. Use of intermittent rifampin and pyrazinamide therapy for latent tuberculosis infection in a targeted tuberculin testing program. Clin Infect Dis 2004;39:1764-71.
55. Tramontana JM, Utaipat U, Molloy A et al. Thalidomide treatment reduces tumor necrosis factor alpha production and enhances weight gain in patients with pulmonary tuberculosis. Mol Med 1995; 1:384-97.
56. Wallis RS, Kyambadde P, Johnson JL et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-associated tuberculosis. Aids 2004;18:257-64.
57. Nathan C, Sporn M. Cytokines, in context. J Cell Biol 1991;113:981-6.
58. Abraham E. Why immunomodulatory therapies have not worked in sepsis. Intensive Care Med 1999;25:556-66.